BS_GR46VD0Q
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 249.96714848883047
- age_years
- 4.304
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.359
- DNA_REPAIR+0.186
- PANCREAS_BETA_CELLS+0.105
- KRAS_SIGNALING_DN+0.063
- BILE_ACID_METABOLISM+0.057
- UV_RESPONSE_DN+0.054
- SPERMATOGENESIS+0.011
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.006
- XENOBIOTIC_METABOLISM-0.013
- COAGULATION-0.028
Top 10 suppressed
- MTORC1_SIGNALING-0.442
- OXIDATIVE_PHOSPHORYLATION-0.410
- CHOLESTEROL_HOMEOSTASIS-0.384
- E2F_TARGETS-0.374
- G2M_CHECKPOINT-0.367
- ANDROGEN_RESPONSE-0.360
- TNFA_SIGNALING_VIA_NFKB-0.329
- INFLAMMATORY_RESPONSE-0.318
- HYPOXIA-0.317
- PROTEIN_SECRETION-0.286
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516050 | — | — | 0.872 |
| 2 | TCGA-OL-A5DA-01A-11R-A27Q-07 | — | B | 0.867 |
| 3 | MDT-AP-1160 | Med | Medulloblastoma | 0.865 |
| 4 | ea635e80-1225-4f52-a6cf-8f4c20201240 | — | — | 0.858 |
| 5 | d2995480-5ae0-42e1-9a21-25e1435201ee | — | — | 0.854 |
| 6 | MBCProject_0814_T1_RNA | — | A | 0.852 |
| 7 | MBCProject_0719_T1_RNA | — | A | 0.851 |
| 8 | MBCProject_3946_T4_RNA | — | A | 0.847 |
| 9 | s0102877 | — | — | 0.843 |
| 10 | 718c4754-af81-496f-878d-83222a2581b8 | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.359 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.186 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.105 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.063 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.057 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.054 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.011 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.006 | Inavolisib | — uncovered |